Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16-02-2021
Gilead to face HIV antitrust claims
05-03-2020
03-02-2022
Sundry Photography / Shutterstock.com
Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline (GSK) subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, HIV, US District Court for the District of Delaware, Shionogi, GlaxoSmithKline